From iron to HIF-PH inhibitors: rethinking anemia management after kidney transplant
Authors:
- Anna De AmiciAAAnna De Amici
- Chiara De LisoCLChiara De Liso
- Anna PisacretaAPAnna Pisacreta
- Margherita Di NaroMNMargherita Di Naro
- Lara CaldiroliLCLara Caldiroli
- Paolo MolinariPMPaolo Molinari
- Anna RegaliaARAnna Regalia
- Emilietta BrigatiEBEmilietta Brigati
- Simona VerdescaSVSimona Verdesca
- Marco MaggiMMMarco Maggi
- Matteo Tommaso RighiMRMatteo Tommaso Righi
- Michele FilippiMFMichele Filippi
Open Access
- 13 January 2026
- journal article
- Published by Aboutscience Srl in Giornale di Clinica Nefrologica e Dialisi
- Vol. 38 (1) , 100-106
Abstract
Anemia is one of the most common complications in patients undergoing kidney transplantation, with an estimated prevalence between 30% and 50%, especially in the first six months after transplantation. The pathogenesis of anemia in these patients is multifactorial, related to chronic inflammation, disorders of iron metabolism, myelosuppression from several immunosuppressive drugs, and hormonal and metabolic alterations. The clinical implications of anemia in kidney transplants are significant: it is a negative prognostic factor for patient and transplant survival, significantly affecting cardiovascular risk and quality of life. This review analyzes in detail the pathogenic mechanisms of anemia in the post-transplant context, illustrating their clinical impact and providing an updated overview of currently available therapeutic strategies, with a focus on new molecules belonging to the class of prolyl-hydroxylase inhibitors (HIF-PHi), which are revolutionizing the therapeutic approach to anemia secondary to renal failure.Keywords
This publication has 30 references indexed in Scilit:
- Roxadustat for CKD-related anemia: a unified solution for non-dialysis, dialysis, and post-transplant patientsInternational Urology and Nephrology, 2025
- The Efficacy and Safety of Roxadustat for the Treatment of Posttransplantation Anemia: A Randomized StudyKidney International Reports, 2024
- Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceKidney International, 2023
- Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysisCochrane Database of Systematic Reviews, 2023
- Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase InhibitorsDrugs, 2022
- Evaluating the safety and efficacy of daprodustat for anemia of chronic kidney disease: a meta-analysis of randomized clinical trialsEuropean Journal of Clinical Pharmacology, 2022
- Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)Advances in Therapy, 2021
- Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney diseaseKidney International Supplements, 2021
- Roxadustat for CKD-related Anemia in Non-dialysis PatientsKidney International Reports, 2021
- Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and managementAmerican Journal of Hematology, 2017